The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages 755-758

  Ozkan, Elgin ^a   Soydal, Cigdem ^a   Araz, Mine ^a   Aras, Gulseren ^a   Ibis, Erkan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

18F FDG PET CT; antithyroglobulin antibody; differentiated thyroid cancers

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIATED THYROID CANCER; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PREDICTIVE VALUE;

AUTOANTIBODIES; CELL DIFFERENTIATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; THYROID NEOPLASMS;

EID: 84863861301     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31825ae77b     Document Type: Article

References (18)

1. Filesi M, Signore A, Ventroni G, et al. Role of initial iodine-131 wholebody scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39:1542-1546. (Pubitemid 28459883)
2. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patientswith differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249-252. (Pubitemid 28154769)
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma [review]. N Engl J Med. 1998;338:297-306. (Pubitemid 28065257)
4. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885. (Pubitemid 30644169)
5. Demers LM, Spencer CA, eds. Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease.Washington, DC: National Academy of Clinical Biochemistry - Professional Association; 2002:125.
6. Aras G, Gültekin SS, Küçük NO. The additive clinical value of combined thyroglobulin and TgAb measurements to define persistent and recurrent disease in patients with differentiated thyroid cancer. Nucl Med Commun. 2008;29:880-884.
7. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121-1127. (Pubitemid 28496379)
8. Ericsson UB, Christensen SB, Thorell JI. A high prevalence of thyroglobulin autoantibodies in adults with and without thyroid disease as measured with a sensitive solid-phase immunosorbent radioassay. Clin Immunol Immunopathol. 1985;37:154-162. (Pubitemid 15239401)
9. Kumar A, Shah DH, Shrihari U, et al. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid. 1994;4:199-202. (Pubitemid 24202356)
10. Pacini F, Mariotti S, Formica N, et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol (Copenh). 1988;119:373-380.
11. Rubello D, Girelli ME, Casara D, et al. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 1990;13:737-742.
12. Rubello D, Casara D, Girelli ME, et al. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med. 1992;33:1478-1480.
13. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med. 2003;139:346-351.
14. Seo JH, Lee SW, Ahn BC, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of TgAb: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) . 2010;72:558-563.
15. 131I scan. Rev Esp Med Nucl. 2011;30:77-82.
16. Feldt-Rasmussen U, Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. J Endocrinol Invest. 1988;11: 175-181.
17. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem. 1996;42:164-173. (Pubitemid 26030404)
18. 18F-fuorodeoxyglucose -positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun. 2011;32:245-251.